Phase 1C definition

Phase 1C means that part of the Toll Road between May Pen and Williamsfield as more particularly described in Schedule 3;
Sample 1Sample 2
Phase 1C means the Plot Development and the Critical Infrastructure listed below all of which Critical Infrastructure shall be in accordance with the Primary Development Delivery Programme pursuant to the relevant Overarching Delivery Obligations and all relevant Phase 1C Necessary Consents and the relevant Phase 1C Details (subject to any amendments approved in accordance with Condition 4.2 of the S73 Permission):
Sample 1Sample 2
Phase 1C as shown on Exhibit A-l.
Sample 1

Examples of Phase 1C in a sentence

  • Close-out nearing completion.• Phase 1C – Substantially Complete.

  • For the operations of Rea Vaya Phase 1B and Phase 1C two Depots and two Terminals are required.

  • The first Depot is located in Selby and it will be a full Depot that will be shared between Phase 1B and Phase 1C operations.

  • This project is one of the Rea Vaya Phase 1C complementary routes.

  • Phase 1C- This involves the refurbishment of Ward 47 to accommodate Adult Rehab/Continuing care and to facilitate the move out of the Orchards.

  • These include recommendations regarding adding those 75 years of age and older and frontline essential workers into Phase 1B and the creation of a Phase 1C that contains individuals ages 65-74, ages 16-64 with an underlying health condition putting them at severe risk for COVID-19, and essential workers not included in 1B.

  • Through this planned development process, the applicant seeks approval for the alternative proposed access: • Lots 21-32 in Phase 1A, Lots 44-49 in Phase 1B, and Lots 69-77 in Phase 1C have over 25-feet of frontage on the proposed public alley at the rear of the lot, and 25-feet of frontage on the proposed common area tract with a pedestrian way at the front of the lot.

  • Allocation is dependent on vaccine supply.● Prioritize Marylanders who are 75 and older in Phase 1B, and Marylanders who are 65 and older in Phase 1C.

  • Allocation is dependent on vaccine supply.• Prioritize Marylanders who are 75 and older in Phase 1B, and Marylanders who are 65 and older in Phase 1C.

  • A third subphase, Phase 1C was added to decouple BA and SOP production in Phase 1B resulting in: • Phase 1A targeting production of 20 kstpa of SOP (K2SO4) and 9 kstpa of BA (H3BO3) • Phase 1B targeting SOP production at a rate of 60 kstpa • Phase 1C targeting BA production at a rate of 81 kstpa.


More Definitions of Phase 1C

Phase 1C. RISK BASED RENEWAL PRIORITIZATION
Sample 1
Phase 1C means:all Plot Development; andother Critical Infrastructure and works, forming part of the Southern Development within Phase 1 as shown for indicative purposes on Plan 12 in Schedule 8 to the S106 Agreement (but not including anything within Phases 1A or 1B) the Critical Infrastructure element of which shall be delivered in accordance with the Primary Development Delivery Programme pursuant to the relevant Overarching Delivery Obligations and all relevant Phase 1C Necessary Consents and the relevant Phase 1C Details (subject to any amendments approved in accordance with Condition 4.2); "Phase 1C” means the following Plot Development and the Critical Infrastructure, the Critical Infrastructure element of which shall be delivered in accordance with the Primary Development Delivery Programme pursuant to the relevant Overarching Delivery Obligations and all relevant Phase 1C Necessary Consents and the relevant Phase 1C Details (subject to any amendments approved in accordance with Condition 4.2):(a) Plot Development in relation to Plots 11,13 and 62;(b) Community Facilities (Market Quarter Zone) (if not provided as part of Phase 1B (South));(c) Temporary Health Centre; and(d) Neighbourhood Police Unit (Market Quarter); “Phase 2 (South)” means:
Sample 1
Phase 1C. Firm-Fixed Price = $200,000.00 Software License (SMMP(R)). This offer by MACHINETALKER for the purchase of the Software License shall be accepted or rejected at the sole discretion of KBR, but acceptance by KBR must be in the form of a Lump Sum payment received by MACHINETALKER prior to 11:59pm on 01 April 2005. In the event KBR elects to purchase the Software License, said License terms and conditions shall be as set forth in Exhibit 6 of this Agreement. In the event KBR elects to end the project, or fail to purchase the Software License, 1) KBR shall waive any and all rights to the licenses technology and products, 2) KBR and MACHINETALKER shall cease to have any right and/or obligation to each other and 3) MACHINETALKER shall be free of all encumbrances and limitations on the intellectual property rights as it applies to the licensed technology and products.
Sample 1
Phase 1C. Firm-Fixed Price = $200,000.00 Software License (SMMP(R)). This offer by MACHINETALKER for the purchase of the Software License shall be accepted or rejected at the sole discretion of KBR, but acceptance by KBR must be in the form of a Lump Sum payment received by MACHINETALKER prior to 11:59pm on 01 April 2005. In the event KBR elects to purchase the Software License, said License terms and conditions shall be as set forth in Exhibit 6 of this Agreement. In the event KBR elects to end the project, or fail to purchase the Software License, 1) KBR shall waive any and all rights to the licenses technology and products, 2) KBR and MACHINETALKER shall cease to have any right and/or obligation to each other and 3) MACHINETALKER shall be free of all encumbrances and limitations on the intellectual property rights as it applies to the licensed technology and products. Invoices shall be submitted to: Xxxxxxx Xxxxx & Root Services, Inc. X.X. Xxx 00000Xxxxxxxxx, Xxxxxxxx 00000-0000 Attention: Procurement - Xx. Xxxxx X. Shriner MACHINETALKER shall execute and submit one (1) copy of the "Affidavit for Subcontractor" incorporated as Exhibit 2 with the final invoice.
Sample 1
Phase 1C. Ref: 2017/03358/RES: Submission of Reserved Matters Application to discharge access, appearance, landscaping, layout, and scale pursuant to Condition 1 for the land identified as Exhibition Green within the masterplan for the M&S Site redevelopment, pursuant to Outline Planning Permission reference 2014/04726/OUT, approved on 16th December 2015. Approved 13 March 2018.
Sample 1
Phase 1C. Retrospective testing in […***…] of PHARMA’s […***…] clinical samples.
Sample 1

Related to Phase 1C

  • Phase 1 means the phase of the ATP comprised of: (1) improvements to the State Street Substation; (2) construction of the Proposed Line; (3) the rebuilding of NYSEG’s existing Lines 971 and 000 xxxxx xx Xxxxxxxx Xxxx xx the NYSEG ROW to allow for construction of the Proposed Line as intended; (4) improvements to the Elbridge Substation to accept the Proposed Line; and (5) National Grid’s conveyance to NYSEG of the NYSEG Acquired ROW and such other land interests as contemplated by the Purchase and Sale Agreement.

  • Phase 2 means the phase of the ATP comprised of: (1) improvements to the State Street Substation to receive Rebuilt Line 972; (2) the rebuilding of NYSEG’s existing Line 972 not performed in Phase 1; (3) construction of Relocated Line 15; (4) the construction of Bused Line 5; (5) improvements to the Elbridge Substation to receive Relocated Line 15; and (6) improvements to the Elbridge Substation to receive Bused Line 5.

  • Phase 1 Study means a clinical study of a drug candidate in human patients with the primary objective of characterizing its safety, tolerability, and pharmacokinetics and identifying a recommended dose and regimen for future studies as described in 21 C.F.R. §312.21(a), or a comparable clinical study prescribed by the relevant Regulatory Authority in a country other than the United States. The drug candidate can be administered to patients as a single agent or in combination with other investigational or marketed agents.

  • Phase III means human clinical trials, the principal purpose of which is to establish substantial evidence of both safety and efficacy in patients with the disease or condition being studied, as more fully defined in 21 C.F.R. §312.21(c) or similar clinical study in a country other than the United States. Phase III shall also include any other human clinical trial intended to serve as a pivotal trial to support the submission of an application for regulatory approval.

  • Phase 3 means the period commencing on the day after the Phase 2 implementation date and ending on the Phase 3 implementation date (as defined below).

  • Phase II means the second part of the tuition incentive assistance program which provides assistance in the third and fourth year of 4-year degree programs.

  • Study Completion means the database for the Study has been locked and all Essential Documents have been provided to the Sponsor, including a copy of the letter from the Reviewing HREC acknowledging receipt of the final report and/or closure letter from the Principal Investigator.

  • Phase 1 Clinical Trial means a Clinical Trial of a Product on sufficient numbers of normal volunteers and/or patients that is designed to establish that such Product is safe for its intended use and to support its continued testing in Phase 2 Clinical Trials. For purposes of this Agreement, ‘initiation’ of a Phase 1 Clinical Trial for a Product means the first dosing of such Product in a human subject in a Phase 1 Clinical Trial.

  • Phase I Study means a study in humans which provides for the first introduction into humans of a product, conducted in healthy volunteers or patients to obtain information on product safety, tolerability, pharmacological activity or pharmacokinetics, as more fully defined in 21 C.F.R. § 312.21(a) (or the non-United States equivalent thereof).

  • Phase 2 Clinical Trial means a human clinical trial, for which the primary endpoints include a determination of dose ranges or an indication of efficacy in patients being studied as described in 21 C.F.R. §312.21(b), or an equivalent clinical trial in a country in the Territory other than the United States.

  • Phase or “Phases” in respect of the Project shall mean that the components of the Project are placed in service during more than one year during the Investment Period, and the word “Phase” shall therefore refer to the applicable portion of the Project placed in service in a given year during the Investment Period.

  • Development Phase means the period before a vehicle type is type approved.

  • Phase 1 Trial means, with respect to a Licensed Product, a clinical trial (or — in case of a multi-phase clinical trial — those parts of a clinical trial) in line with the provisions of 21CFR312, Section 21 (a).

  • project completion period means the period of sixty (60) months commencing from and expiring on for the construction and obtaining of Temporary Occupation Permit or Permits for the whole of the Development as provided in clause 3.3;

  • Phase I means the first part of the tuition incentive assistance program defined as the academic period of 80 semester or 120 term credits, or less, leading to an associate degree or certificate.

  • Phase I Clinical Study means a human clinical study of a product, the principal purpose of which is a preliminary determination of safety in healthy individuals or patients, as described in 21 C.F.R. 312.21(a).

  • Phase I Clinical Trial means a human clinical trial that is intended to initially evaluate the safety and/or pharmacological effect of a Product in subjects or that would otherwise satisfy requirements of 21 C.F.R. 312.21(a), or its foreign equivalent.

  • Phase IIb Clinical Trial means a clinical trial of a Product on sufficient numbers of patients that is designed to provide a preliminary determination of safety and efficacy of such Product in the target patient population over a range of doses and dose regimens.

  • Phase II Study means a human clinical trial, for which the primary endpoints include a determination of dose ranges and/or a preliminary determination of efficacy in patients being studied as described in 21 C.F.R. § 312.21(b) (FDCA), as amended from time to time, and the foreign equivalent thereof.

  • Phase 4 Clinical Trial means a Clinical Trial of a Product conducted after Regulatory Approval of such Product has been obtained from an appropriate Regulatory Authority, which trial is (a) conducted voluntarily by a Party to enhance marketing or scientific knowledge of the Product, or (b) conducted due to a request or requirement of a Regulatory Authority.

  • Project Completion means the date, as determined by the Division after consultation with the Recipient, that operation of the Project is initiated or is capable of being initiated, whichever comes first.

  • Phase 3 Study means a clinical study of a drug candidate in human patients that incorporates accepted endpoints for confirmation of statistical significance of efficacy and safety with the aim to obtain Regulatory Approval in any country as described in 21 C.F.R. 312.21(c), or a comparable clinical study prescribed by the relevant Regulatory Authority in a country other than the United States. The relevant drug candidate may be administered to patients as a single agent or in combination with other investigational or marketed agents.

  • Phase 3 Clinical Trial means a pivotal clinical trial in humans performed to gain evidence with statistical significance of the efficacy of a product in a target population, and to obtain expanded evidence of safety for such product that is needed to evaluate the overall benefit-risk relationship of such product, to form the basis for approval of an NDA and to provide an adequate basis for physician labeling, as described in 21 C.F.R. § 312.21(c) or the corresponding regulation in jurisdictions other than the United States.

  • Project Completion Date means the date on which the Completion Certificate is issued;

  • Phase II Clinical Study means a human clinical study of a product initiated to determine the safety and efficacy in the target patient population, as described 21 C.F.R. 312.21(b).

  • Phase II Clinical Trial means a controlled human clinical study that would satisfy the requirements of 21 CFR 312.21(b), conducted to study the effectiveness and establish the dose range of a Product for a particular Indication in patients with the disease or condition under study, including a Phase IIA Clinical Study or Phase IIB Clinical Study.